 |
|
|
| |
Durable Suppression 2 Years After Switch to DTG +
RPV 2-Drug Regimen: SWORD-1 and SWORD-2 Studies
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Aboud M,1Orkin C,2Podzamczer D,3Bogner J,4Baker D,5Khuong-Josses M-A,6Parks D,7Angelis K,8Kahl L,1Blair E,9Underwood M,9Wynne B,10Vandermeulen K,11Gartland M,9Smith K9
1ViiV Healthcare, Brentford, UK; 2Barts Health NHS Trust, London, UK; 3Hospital Universitari de Bellvitge, Barcelona, Spain; 4Hospital of the University of Munich, Munich, Germany; 5East Sydney Doctors, Darlinghurst, Sydney, Australia; 6CHG -Hopital Delafontaine, Saint Denis Cedex, France; 7Central West Clinical Research, St Louis, MO, USA; 8GlaxoSmithKline, Uxbridge, UK; 9ViiV Healthcare, Research Triangle Park, NC, USA; 10ViiV Healthcare, Collegeville, PA, USA; 11Janssen Pharmaceutica NV, Beerse, Belgium
|
| |
|
|
|
|
|
